Literature DB >> 27890421

Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.

E Belousova1, G Karmazanovsky2, A Kriger3, D Kalinin4, L Mannelli5, A Glotov4, N Karelskaya6, O Paklina7, A Kaldarov3.   

Abstract

AIM: To identify the multidetector computed tomography (MDCT) features of pancreatic neuroendocrine tumours (pNETs), which correlate with tumour histology and enable preoperative grading.
MATERIALS AND METHODS: Thirty-nine patients with histologically confirmed pNET who underwent preoperative contrast-enhanced MDCT were included in this study. Nineteen tumours were classified as Grade 1 (G1) and 20 as Grade 2 (G2). Histopathology slides were reviewed to assess the intratumoural microvascular density (MVD) and the amount of tumour stroma. Computed tomography (CT) image analysis included tumour size, margin delineation, calcifications, homogeneity, contrast enhancement (CE) pattern, tumour absolute and relative enhancement, presence of cystic changes, pancreatic duct dilatation, regional and distant metastases. The diagnostic ability to predict tumour grade was measured for each MDCT finding and their combinations.
RESULTS: The mean arterial enhancement ratio had a mean±standard deviation of 1.53±0.45 in G1 and 1.01±0.33 in G2 pNETs (p=0.0003) and correlated with intratumoural microvascular density (MVD; r=0.55, p=0.0002). Tissue stroma percentage did not correlate with imaging findings. Late CE of the tumour (the peak attenuation observed in the venous phase) was significantly associated with G2. Tumour size >20 mm, arterial enhancement ratio <1.1, and late CE showed 74.4%, 79.5%, and 74.4% accuracy, respectively, in diagnosing G2 tumours, while the accuracy of at least two of these criteria used in combination was 82%. Based on these results, a diagnostic algorithm was proposed, which showed high interobserver agreement (k=0.82) in the prediction of tumour grade.
CONCLUSION: Contrast-enhanced MDCT features correlate with histological findings and enable the differentiation between G1 and G2 pNETs during preoperative examination.
Copyright © 2016 The Royal College of Radiologists. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27890421      PMCID: PMC5552195          DOI: 10.1016/j.crad.2016.10.021

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  29 in total

1.  Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors.

Authors:  Yu Takahashi; Yuri Akishima-Fukasawa; Noritoshi Kobayashi; Tsuyoshi Sano; Tomoo Kosuge; Yuji Nimura; Yae Kanai; Nobuyoshi Hiraoka
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

2.  Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT.

Authors:  Satomi Kawamoto; Pamela T Johnson; Chanjuan Shi; Aatur D Singhi; Ralph H Hruban; Christopher L Wolfgang; Barish H Edil; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

3.  Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Authors:  George A Poultsides; Lyen C Huang; Yijun Chen; Brendan C Visser; Reetesh K Pai; R Brooke Jeffrey; Walter G Park; Ann M Chen; Pamela L Kunz; George A Fisher; Jeffrey A Norton
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

Review 4.  Multimodality preoperative imaging of pancreatic insulinomas.

Authors:  G McAuley; H Delaney; J Colville; I Lyburn; D Worsley; P Govender; W C Torreggiani
Journal:  Clin Radiol       Date:  2005-10       Impact factor: 2.350

5.  Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.

Authors:  Koji Takumi; Yoshihiko Fukukura; Michiyo Higashi; Junnichi Ideue; Tomokazu Umanodan; Hiroto Hakamada; Ichiro Kanetsuki; Takashi Yoshiura
Journal:  Eur J Radiol       Date:  2015-05-14       Impact factor: 3.528

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma.

Authors:  Jung Hoon Kim; Hyo Won Eun; Young Jae Kim; Jeong Min Lee; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

8.  Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study.

Authors:  H J Durán; B Ielpo; E Díaz; I Fabra; R Caruso; L Malavé; O Cano-Valderrama; L Garcia; Y Quijano; E Vicente
Journal:  Int J Surg       Date:  2016-04-06       Impact factor: 6.071

9.  Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.

Authors:  Jordan M Cloyd; Kimberly E Kopecky; Jeffrey A Norton; Pamela L Kunz; George A Fisher; Brendan C Visser; Monica M Dua; Walter G Park; George A Poultsides
Journal:  Surgery       Date:  2016-05-20       Impact factor: 3.982

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  18 in total

1.  CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.

Authors:  Dongsheng Gu; Yabin Hu; Hui Ding; Jingwei Wei; Ke Chen; Hao Liu; Mengsu Zeng; Jie Tian
Journal:  Eur Radiol       Date:  2019-06-21       Impact factor: 5.315

2.  Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT.

Authors:  Ferdinand Seith; Christina Schraml; Gerald Reischl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère; Nina Schwenzer
Journal:  Radiol Med       Date:  2018-06-30       Impact factor: 3.469

3.  Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Yun Bian; Zengrui Zhao; Hui Jiang; Xu Fang; Jing Li; Kai Cao; Chao Ma; Shiwei Guo; Li Wang; Gang Jin; Jianping Lu; Jun Xu
Journal:  J Magn Reson Imaging       Date:  2020-04-28       Impact factor: 4.813

4.  Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.

Authors:  Giuseppe Corrias; Serena Monti; Natally Horvat; Laura Tang; Olca Basturk; Luca Saba; Lorenzo Mannelli
Journal:  Clin Imaging       Date:  2018-02-08       Impact factor: 1.605

5.  Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms.

Authors:  Wataru Izumo; Ryota Higuchi; Toru Furukawa; Takehisa Yazawa; Shuichiro Uemura; Yutaro Matsunaga; Masahiro Shiihara; Yukiko Takayama; Junko Tahara; Kyoko Shimizu; Katsutoshi Tokushige; Masakazu Yamamoto
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 6.  New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.

Authors:  Mohammed Saleh; Priya R Bhosale; Motoyo Yano; Malak Itani; Ahmed K Elsayes; Daniel Halperin; Emily K Bergsland; Ajaykumar C Morani
Journal:  Abdom Radiol (NY)       Date:  2020-10-23

7.  Does Second Reader Opinion Affect Patient Management in Pancreatic Ductal Adenocarcinoma?

Authors:  Giuseppe Corrias; Sandra Huicochea Castellanos; Ryan Merkow; Russel Langan; Vinod Balachandran; Monica Ragucci; Gabriella Carollo; Marcello Mancini; Luca Saba; Lorenzo Mannelli
Journal:  Acad Radiol       Date:  2018-01-17       Impact factor: 3.173

8.  Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance.

Authors:  Chuan-Gen Guo; Shuai Ren; Xiao Chen; Qi-Dong Wang; Wen-Bo Xiao; Jing-Feng Zhang; Shao-Feng Duan; Zhong-Qiu Wang
Journal:  Cancer Manag Res       Date:  2019-03-04       Impact factor: 3.989

9.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

10.  Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Authors:  Giuseppe Corrias; Natally Horvat; Serena Monti; Olca Basturk; Oscar Lin; Luca Saba; Lisa Bodei; Diane L Reidy; Lorenzo Mannelli
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.